Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ARTEMIS-001: HS-20093 in advanced solid tumors
NCT05276609Phase 1Unknown
- Sponsor
- Hansoh Pharmaceutical Group
- Start
- Nov 2021
- Primary completion
- Dec 2023
- Modality
- Antibody-Drug Conjugates (ADCs)
- Countries
- 1
01
Overview
Phase 1, open-label trial of risvutatug rezetecan in solid tumor (advanced stage), non-small cell lung cancer (NSCLC), small cell lung cancer (SCLC) and 3 more (2 arms), sponsored by Hansoh Pharmaceutical Group. Primary endpoints: Maximum Tolerated Dose at 21 days and Objective Response Rate at 24 months. Status: unknown.
02
Drugs
risvutatug rezetecan
03
Conditions
solid tumor (advanced stage)non-small cell lung cancer (NSCLC)small cell lung cancer (SCLC)metastatic castration-resistant prostate cancer (mCRPC)esophageal carcinoma
Beyond the preview
Go deeper on NCT05276609.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05276609.